MARKET

ASRT

ASRT

Assertio Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7779
+0.0054
+0.70%
Closed 16:00 08/13 EDT
OPEN
0.7743
PREV CLOSE
0.7725
HIGH
0.7987
LOW
0.7560
VOLUME
620.55K
TURNOVER
--
52 WEEK HIGH
1.710
52 WEEK LOW
0.5500
MARKET CAP
83.33M
P/E (TTM)
-0.3694
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ASRT stock price target is 2.425 with a high estimate of 3.500 and a low estimate of 1.350.

EPS

ASRT News

More
Assertio Holdings, Inc. (ASRT) CEO Todd Smith on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 6d ago
More on Assertio Therapeutics Q2 earnings
Assertio Therapeutics (ASRT -15.9%) Q2 GAAP EPS of -$0.35 missed consensus by $0.23. Combined Q2 pro-forma net product sales of $27.7M; Zyla net product sa
seekingalpha · 6d ago
Assertio Therapeutics EPS misses by $0.23, misses on revenue
Assertio Therapeutics (NASDAQ:ASRT): Q2 GAAP EPS of -$0.35 misses by $0.23. Revenue of $20.62M (-64.0% Y/Y) misses by $4.71M. Shares +1% PM. Press Release
seekingalpha · 6d ago
Assertio (ASRT) Reports Q2 Loss, Misses Revenue Estimates
Assertio (ASRT) delivered earnings and revenue surprises of -100.00% and -18.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 6d ago
Recap: Assertio Holdings Q2 Earnings
Shares of Assertio Holdings (NASDAQ:ASRT) moved higher by 0.9% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were down 33.33% over the past year to ($0.28), which missed the estimate of ($0.03).Revenue of $20,
Benzinga · 6d ago
Assertio Reports Second Quarter 2020 Financial Results
\--Completed all merger and integration activities in Q2-- \--Repaid $10 million of Senior Secured Notes ahead of schedule-- \--Zyla products partially contributed to Q2 net product sales of $20.2 million-- \--Combined second quarter 2020 net product sale
GlobeNewswire · 6d ago
Preview: Assertio Therapeutics's Earnings
Assertio Therapeutics (NASDAQ: ASRT) will be releasing its next round of earnings this Friday, August 07. For all of the relevant information, here is your guide for Friday's Q2 earnings announcement.Earnings and Revenue Wall Street expects an EPS loss $-0.03
Benzinga · 08/06 19:50
Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/31 16:30

Industry

Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-0.06%

Hot Stocks

Symbol
Price
%Change

About ASRT

Assertio Holdings, Inc. is a specialty pharmaceutical company. The Company owns a portfolio of prescription neurology, inflammation and pain medications. Its marketed products include Cambia (diclofenac potassium) for Oral solution, INDOCIN Oral Suspension, INDOCIN (indomethacin) Suppositories, OXAYDO tablets, SPRIX Nasal Spray, VIVLODEX capsules, ZIPSOR Liquid filled capsules and ZORVOLEX capsules. The Company is also focused on developing and commercializing neurology, orphan and specialty medicines. Its pipeline products include Diclofenac Potassium, Long-acting Cosyntropin and Diclofenac potassium. Diclofenac Potassium is being developed for mild/moderate acute pain. Long-acting Cosyntropin is being developed for diagnosis of adrenal insufficiency. Diclofenac potassium is a liquid formulation being developed for acute migraine attacks.
More

Webull offers kinds of Assertio Holdings Inc stock information, including NASDAQ:ASRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASRT stock methods without spending real money on the virtual paper trading platform.